Market research
4517.TSE Biofermin Pharmaceutical Co., Ltd
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 37B
- P/E ratio
- 24.23
- Analyst target
- Not available
- Dividend yield
- 2.3%
- Beta
- 0.21
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- JP3799800002
- Market cap
- 37B
- P/E ratio
- 24.23
- Analyst target
- Not available
- Dividend yield
- 2.3%
- Beta
- 0.21
About
About Biofermin Pharmaceutical Co., Ltd
Biofermin Pharmaceutical Co., Ltd. manufactures and sells drugs and quasi-drugs in Japan. It offers drugs for the treatment of diarrhea, constipation, and stomach digestion; and veterinary medicines, pesticides and other chemicals, cosmetics, medical equipment, foods, beverages, food additives, feeds, feed additives, and various tests. The company was formerly known as Kobe hygiene Laboratory Co., Ltd. and changed its name to Biofermin Pharmaceutical Co., Ltd. in March 1949. The company was founded in 1917 and is headquartered in Kobe, Japan. Biofermin Pharmaceutical Co., Ltd. is a subsidiary of Taisho Pharmaceutical Holdings Co., Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4517.TSE discussion.
5 years, 6 months ago
Biofermin Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 9.1% above its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Biofermin Pharmaceutical Co., Ltd's total revenue sank by 11.4% to $3B since the same quarter in the previous year.
Its net income has dropped by 40.8% to $516M since the same quarter in the previous year.
Based on the above factors, Biofermin Pharmaceutical Co., Ltd gets an overall score of 2/5.